VERAXA Biotech presents BiTAC-ADC proof-of-concept data
VERAXA Biotech presented in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress.
Story updates
11:01:52 AM UTC
SquawkNews
In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activityZURICH, SWITZERLAND — October 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer ther…